The China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chains, capital, and talent moving through a landscape of heightened scrutiny and shifting trust. For many companies and investors, on both sides, navigating this landscape has become a strategic necessity rather than a theoretical risk. This high-level panel brings together influential voices to discuss how the biotech ecosystem can continue to thrive amid these realities. The discussion will focus on practical pathways to mutual success, including how to structure partnerships, manage risk, maintain scientific exchange, and identify areas where collaboration remains both viable and valuable in a rapidly changing environment.